AUTHORS
Genesis Snyder, Alexia Martin2, Yasemin Sezgin3, Colin Maguire4, Branden Moriarity, PhD5, Beau Webber, PhD6, Erin Robinson7, Marcelo De Souza Pereira, PhD8, Noushin Saljoughian9, Misaal Mehboob10, Ana Portillo11, Justin Lyberger12, Kevin Cassady13, Ali Ashkar, DVM, PhD14, Gregory Behbehani, MD, PhD15, Dean A Lee, MD.PhD16, Meisam Naeimi Kararoudi, DVM PhD17
AFFILIATIONS
1 Nationwide Children's Hospital, Columbus, Ohio, United States
2 Nationwide Children's Hospital, Columbus, Ohio, United States
3 Cincinnati Childrens Hospital, Cincinnati, Ohio, United States
4 Nationwide Children's Hospital, Columbus, Ohio, United States
5 Masonic Cancer Center, Minneapolis, Minnesota, United States
6 Masonic Cancer Center, Minneapolis, Minnesota, United States
7 Kromatid, Longmont, Colorado, United States
8 Nationwide Children's Hospital, Columbus, Ohio, United States
9 Nationwide Children's Hospital, Columbus, Ohio, United States
10 McMaster University, Hamilton, Ontario, Canada
11 McMaster University, Hamilton, Ontario, Canada
12 The Ohio State University, Columbus, Ohio, United States
13 Nationwide Children's Hospital, Columbus, Ohio, United States
14 McMaster University, Hamilton, Ontario, Canada
15 The Ohio State University, Columbus, Ohio, United States
16 Nationwide Children's Hospital, Columbus, Ohio, United States
17 Cincinnati Children's Hospital Medical Center and Applied Gene and Cell Therapy Center, Cincinnati, Ohio, United States
ABSTRACT
Relapsed and refractory T cell malignancies are associated with poor clinical outcomes.
Autologous sources of αβT cells have been employed for chimeric antigen receptor (CAR)
therapies to eliminate the potential for graft-vs-host disease (GvHD). However, the
application of CAR-T therapy for T-ALL has been hindered by an inability to obtain sufficient
healthy αβT cells from patients combined with fratricide due to concurrent antigen
expression on normal T cells. Here, we genetically engineered polyclonal γδT cells, which do
not cause GvHD, as an allogeneic source for cancer immunotherapy targeting the pan-
cancer antigen CD38. Utilizing a novel expansion protocol in combination with CRISPR/AAV
gene editing, we developed CD38KO/CD38-CAR polyclonal γδT cells that target T-ALL. Our
editing strategy enabled site-directed, on-target insertion of the CD38-CAR transgene into
the CD38 locus, with no evidence of significant random CAR DNA integration (as commonly
seen with lentiviral CAR transduction) or chromatin abnormalities resulting from CRISPR
editing. This enhanced targeting effectively mitigated fratricide through simultaneous CD38
disruption and CAR expression. We demonstrated the efficacy of the CD38KO/CD38-CAR
γδT cells in vitro across multiple patient-derived T-ALL samples collected at baseline and
relapse. In vivo, a single injection of CD38KO/CD38-CAR γδT cells without exogenous
cytokine support resulted in potent anti-leukemic efficacy. Fratricide-resistant
CD38KO/CD38-CAR polyclonal γδT cells thus represent a promising off-the-shelf
therapeutic platform for T cell malignancies and other CD38-expressing cancers including AML, Burkytt Lymphoma and Multiple Myeoloma.
DISCLOSURES
Meisam Naeimi Kararoudi, DVM PhD: CARTx Therapeutics - Current equity holder in private company; CARTx Therapeutics - Current Employment